Search results for: Determining Value
Filter search results
Improving the Measurement of Valued Output in Primary Care in England
1 August 2022
…elements that confer value to the output. We chose the perspective of the healthcare decision maker in England, whose objective is to maximise health. Hence, valued output in this study…
Update: Value-Based Pricing in the UK
11 January 2011
Value-based pricing for new medicines, proposed as part of UK health care reform, would create a QALY-plus approach for drugs approved starting 1 January 2014. For new drugs, this would…
The Value of Diagnostic information (VODI) in Heart Failure – Recognising Value Beyond ‘Beats-Per-Minute’
3 December 2020
…contrast to therapeutics, this value is not observed as a direct clinical benefit and it must be captured through the ‘value chain’ triggered by healthcare professionals with the diagnosis, that…
An eye on sustainability at the Economist’s Future of Health Europe
30 October 2023
…examples. He also underlined the importance of thinking about a value-based healthcare approach when shaping the care pathway and reframing the common question of ‘can we afford to do this?’…
Pricing and Paying for Cures: Early Experience with HTA of Gene Therapy in the USA
28 February 2019
…value at $46,000 per QALY. Yescarta, at $136,000 per QALY for non-Hodgkin lymphoma, was between “intermediate” and “low” value for money. Second, additional elements of value not usually included in…
The Value of Vaccines in Maintaining Health System Capacity in England
1 October 2021
…treat another. These opportunity costs demonstrate the need to consider health system capacity value, one of the so-called “broader value elements” that is often not fully captured in traditional value…
HTA and Payment Mechanisms for New Drugs to Tackle AMR
23 September 2019
…but are traditionally not considered. These are transmission value, insurance value, diversity value, novel action value, enablement value, and spectrum value. Morton et al. (forthcoming) and Rothery et al. (2018)…
Unlocking the Value of Combination Therapies
9 July 2024
…CTs are increasingly being used in oncology. Key takeaways The current approach to attributing value to therapies used in combination is the incremental value (IV) approach. However, this method faces…
Reconciling MCDA and Augmented Cost-Effectiveness Analysis: Do We Get the Same Decisions?
14 April 2021
…disease being treated. Risk attitudes also impact value trade-offs, with risk aversion reinforcing the effects of these factors on value trade-offs. Reconciling decisions in ACEA and MCDA does require, however,…